In the present invention, there is disclosed a pharmaceutical composition comprising crystalline ziprasidone free base or crystalline ziprasidone hydrochloride particles having a mean particle size equal to or less than about 85 microns and a pharmaceutically acceptable diluent or carrier. There is also disclosed a process for preparing large crystals of ziprasidone hydrochloride monohydrate, comprising the steps of: 1) dissolving ziprasidone free base in a solvent comprising tetrahydrofuran and water, in a volume ratio of about 22 to 35 unit volumes of tetrahydrofuran to about 1.5 to 8 volumes of water; 2) heating the solution resulting from step (1); 3) adding hydrogen chloride to the solution resulting from step (2); and 4) cooling the solution resulting from step (3).
展开▼
